InMed Pharmaceuticals Inc. (INM) Form 424B3 — Oct 28, 2026

InMed Pharmaceuticals filed a supplement to its merger proxy statement/prospectus for the proposed merger with Mentari Therapeutics, Inc. The key change: shareholders of record as of November 5, 2026 (the new CVR Record Date) will receive InMed contingent value rights, replacing the prior 'immediately prior to the First Effective Time' standard. Because shares settle T+1, buyers of INM on or after the CVR record date will not receive CVRs, and shares issued in the merger or via option exercise get none. The shareholder vote on the merger remains set for November 4, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.